ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1446 participants.
Also called NCT05507645
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,446 participants
- Sponsor
- Registry
-
NCT05507645
-
- Other papers using this trial's data
- Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke: The PUMICE Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05507645. Randomized; single masking; primary purpose treatment. Start 2022-11-15 (actual); primary completion 2024-03-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)
- Acronym
- PUMICE
- Condition
- Ischemic Stroke
- Condition
- Mild
- Condition
- Thrombosis
- Intervention (Drug)
- Recombinant Human Prourokinase for Injection (rhPro-UK)
- Intervention (Drug)
- standard medical treatment
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05507645- Content hash
395145434c91e926577d5b534e11006a4e294338368a64bf2e1906ec26a79a6f